Stimulation of insulin-like factor-1 (IGF-1) would increase breast cancer risk and promote relapse. Here we present a case study of a woman with HER2-positive breast cancer that, after chemotherapy and radiotherapy, followed a Healthful Predominantly Plant-basedDiet. This work aimed to ...
First, we will discuss the association between diabetes and cancer, including molecular interactions between IGF-1R and HER2 in BC. Then, the potential role of metformin and other T2DM drugs in the management of HER2-positive BC will be reviewed. Lastly, we conclude with a short summary on ...
Cancer Treat Rev. 2012;38:133–42. Article PubMed Google Scholar Horimoto Y, Ishizuka Y, Ueki Y, Higuchi T, Arakawa A, Saito M. Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients. BMC Cancer. 2022;22:242. Article CAS PubMed ...
In metastatic HER2-low breast cancer, fam-trastuzumab deruxtecan-nxki is the preferred option after patients fail to respond to 1 or 2 lines of chemotherapy.4 HER2+ MBC HER2-positive (HER2+) disease accounts for approximately 15% of MBC and typically has a worse prognosis due to tumor ...
Crown-like structures in breast adipose tissue of breast cancer patients: associations with CD68 expression, obesity, metabolic factors and prognosis Article Open access 22 July 2021 Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing...
BACKGROUND: In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. Ove...
which targets what we now call HER2-low disease. So this is a drug that we use in patients with HER2-positive disease. And then very recently, we identified a significant subset of breast cancer patients who have what's called HER2-low. They would have been previously called HER2-negative...
Combined Immunoscore with regard to Prognostic Stratification involving Initial phase Non-Small-Cell Cancer of the lung. Posted onJanuary 10, 2025 Reply Work specialized in understanding how protected function can be modified with diet has actually revealed extra functions of required nutrients such as ...
Treatment of HER2-positive breast cancer: cur- rent status and future perspectives. Nat Rev Clin Oncol 2012; 9:16-32. 41 Nobles KN, Xiao K, Ahn S, et al. Distinct phosphorylation sites on the beta(2)-adrenergic receptor establish a barcode that encodes differential functions of beta-...
HER2 is an oncogene, expression of which leads to poor prognosis in 30% of breast cancer patients. Although trastuzumab is apparently an effective therapy against HER2-positive tumors, its systemic toxicity and resistance in the majority of patients restricts its applicability. In this study we eval...